DK2112162T3 - Genetisk modificerede humane naturlige dræbercellelinjer - Google Patents

Genetisk modificerede humane naturlige dræbercellelinjer Download PDF

Info

Publication number
DK2112162T3
DK2112162T3 DK09164804T DK09164804T DK2112162T3 DK 2112162 T3 DK2112162 T3 DK 2112162T3 DK 09164804 T DK09164804 T DK 09164804T DK 09164804 T DK09164804 T DK 09164804T DK 2112162 T3 DK2112162 T3 DK 2112162T3
Authority
DK
Denmark
Prior art keywords
natural killer
killer cell
cell lines
genetically modified
modified
Prior art date
Application number
DK09164804T
Other languages
English (en)
Inventor
Kerry S Campbell
Original Assignee
Fox Chase Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35968029&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2112162(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fox Chase Cancer Ct filed Critical Fox Chase Cancer Ct
Application granted granted Critical
Publication of DK2112162T3 publication Critical patent/DK2112162T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
DK09164804T 2004-07-10 2005-07-08 Genetisk modificerede humane naturlige dræbercellelinjer DK2112162T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58658104P 2004-07-10 2004-07-10
EP20050789289 EP1771471B1 (en) 2004-07-10 2005-07-08 Genetically modified human natural killer cell lines

Publications (1)

Publication Number Publication Date
DK2112162T3 true DK2112162T3 (da) 2015-02-23

Family

ID=35968029

Family Applications (4)

Application Number Title Priority Date Filing Date
DK15150984.1T DK2921500T3 (da) 2004-07-10 2005-07-08 Genetisk modificerede, humane, naturlige dræbercellelinjer
DK18169049.6T DK3406631T3 (da) 2004-07-10 2005-07-08 Genetisk modificerede humane naturlige dræbercellelinjer
DK14171739.7T DK2801583T3 (da) 2004-07-10 2005-07-08 Genetisk modificerede humane naturlige dræbercellelinjer
DK09164804T DK2112162T3 (da) 2004-07-10 2005-07-08 Genetisk modificerede humane naturlige dræbercellelinjer

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK15150984.1T DK2921500T3 (da) 2004-07-10 2005-07-08 Genetisk modificerede, humane, naturlige dræbercellelinjer
DK18169049.6T DK3406631T3 (da) 2004-07-10 2005-07-08 Genetisk modificerede humane naturlige dræbercellelinjer
DK14171739.7T DK2801583T3 (da) 2004-07-10 2005-07-08 Genetisk modificerede humane naturlige dræbercellelinjer

Country Status (12)

Country Link
US (8) US7618817B2 (da)
EP (5) EP1771471B1 (da)
AT (1) ATE443084T1 (da)
AU (1) AU2005277831B2 (da)
CA (2) CA3052445C (da)
DE (1) DE602005016683D1 (da)
DK (4) DK2921500T3 (da)
ES (3) ES2955952T3 (da)
HK (2) HK1203975A1 (da)
PL (1) PL2921500T3 (da)
PT (1) PT2921500T (da)
WO (1) WO2006023148A2 (da)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2921500T3 (pl) * 2004-07-10 2024-02-05 The Institute For Cancer Research Genetycznie zmodyfikowane ludzkie linie komórkowe naturalni zabójcy
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
ES2383710T3 (es) 2006-09-08 2012-06-25 Medimmune, Llc Anticuerpos anti-CD19 humanizados y su uso en el tratamiento de tumores, trasplantes y enfermedades autoinmunes
AU2008247382B2 (en) 2007-05-07 2014-06-05 Medimmune, Llc Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2009041113A1 (ja) * 2007-09-28 2009-04-02 Olympus Corporation Fc受容体遺伝子導入ＮＫ細胞、その作製方法、及びこれを用いた抗体依存性細胞障害のアッセイ方法
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX343594B (es) 2007-12-21 2016-11-11 Medimmune Ltd Miembros de union para receptor alfa de interleucina-4 (il-4ra) - 173.
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
CN102438652B (zh) 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
EP2847223B1 (en) 2012-05-07 2019-03-27 Trustees of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
CN118005782A (zh) 2013-10-02 2024-05-10 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
KR20230085215A (ko) 2013-11-01 2023-06-13 이뮤너티바이오, 인크. 종양세포 치사활성 및 항균성 조성물 및 방법
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
CN106715467B (zh) * 2014-03-28 2021-07-27 明尼苏达大学评议会 涉及经工程改造的cd16的多肽、细胞和方法
PT3143134T (pt) 2014-05-15 2020-12-04 Nat Univ Singapore Células assassinas naturais modificadas e seus usos
WO2015179710A1 (en) 2014-05-22 2015-11-26 Conkwest, Inc. Treating solid tumours with nk-92 cells applied by microcatheter
US20170151283A1 (en) * 2014-05-23 2017-06-01 The Trustees Of The University Of Pennsylvania Compositions and methods for treating antibody resistance
US10550197B2 (en) 2014-06-18 2020-02-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus CAR-expressing NK-92 cells as cell therapeutic agents
WO2016057345A1 (en) * 2014-10-06 2016-04-14 Nantkwest, Inc. Treating viral hemorrhagic fever with nk-92 cells
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
IL287051B (en) * 2015-03-27 2022-09-01 Immunitybio Inc nk-2 cells and genetically engineered monoclonal antibodies for cancer treatment
US20170304364A1 (en) * 2015-03-27 2017-10-26 Nantkwest, Inc. Nk-92 cells in combination therapy with cancer drugs
CA2983758A1 (en) 2015-04-25 2016-11-03 The General Hospital Corporation Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
SI3303384T1 (sl) 2015-06-01 2021-11-30 Medimmune Llc Nevtralizirajoče vezavne molekule proti-influenci in njihova uporaba
US10738279B2 (en) 2015-06-10 2020-08-11 Nantkwest, Inc. Modified NK-92 cells for treating cancer
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
DK3317401T3 (da) 2015-07-29 2019-01-02 Onkimmune Ltd Modificerede naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
WO2017049208A1 (en) 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Localized delivery of anti-fugetactic agent for treatment of cancer
US10533157B1 (en) 2015-12-03 2020-01-14 Nantbio, Inc. Recombinant NK cells expressing co-stimulatory molecules
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
EP3408378B1 (en) * 2016-01-25 2022-01-12 NantCell, Inc. Nk cells with altered cxcl12/cxcr4 signaling
WO2017184534A1 (en) * 2016-04-18 2017-10-26 The Gorlin Companies Methods and compositions for improving safety and efficacy of natural killer cell immunotherapy
US20200316118A1 (en) * 2016-05-19 2020-10-08 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
US11419894B2 (en) * 2016-09-16 2022-08-23 The General Hospital Corporation Modified natural killer cells for the treatment of cancer
CA3036713A1 (en) * 2016-09-29 2018-04-05 Nantkwest, Inc. Hla class i-deficient nk-92 cells with decreased immunogenicity
WO2018129199A1 (en) 2017-01-04 2018-07-12 Nova Southeastern University Natural killer (nk) cells expressing an antigen-specific functional t cell receptor (tcr) complex, methods for production thereof, and methods for therapeutic use thereof
AU2018206401B2 (en) 2017-01-06 2022-07-21 Immunitybio, Inc. Genetically modified NK-92 cells with decreased CD96/TIGIT expression
WO2018144777A2 (en) * 2017-02-01 2018-08-09 Nant Holdings Ip, Llc Calreticulin-mediated cancer treatment
AU2018219226A1 (en) 2017-02-07 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018148462A1 (en) * 2017-02-09 2018-08-16 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and compositions and methods thereof
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
WO2018165291A1 (en) 2017-03-08 2018-09-13 Nantkwest, Inc. MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC
MX2019011324A (es) 2017-03-23 2020-01-21 Massachusetts Gen Hospital Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano.
JP7256749B2 (ja) 2017-03-27 2023-04-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における切断されたｎｋｇ２ｄキメラ受容体及びその使用
KR102624509B1 (ko) 2017-03-27 2024-01-12 싱가포르국립대학교 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
AU2018244221B2 (en) * 2017-03-27 2021-06-03 Nantcell, Inc. ANK and IL-12 compositions and methods
JP2020516654A (ja) * 2017-04-13 2020-06-11 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
EP3661561A1 (en) 2017-08-04 2020-06-10 Nantkwest, Inc. Treating and inhibiting leukemia with nk-92 cells
CN111556756A (zh) * 2017-10-26 2020-08-18 明尼苏达大学董事会 重组免疫细胞、制备方法和使用方法
WO2019084284A1 (en) 2017-10-27 2019-05-02 Coneksis, Inc. NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
WO2019089813A1 (en) 2017-11-01 2019-05-09 Nantkwest, Inc. Nk-92 cells to stimulate anti-cancer vaccine
US11779602B2 (en) 2018-01-22 2023-10-10 Endocyte, Inc. Methods of use for CAR T cells
WO2019152513A1 (en) 2018-01-31 2019-08-08 Nantkwest, Inc. Use of 5% human albumin in wash and harvest media
US11813292B2 (en) 2018-03-12 2023-11-14 Immunity Bio, Inc. Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)
US20190321402A1 (en) * 2018-04-19 2019-10-24 Onkimmune Limited Nk cells for use with anitbodies in cancer therapy
CA3099806A1 (en) * 2018-05-14 2019-11-21 Indapta Therapeutics, Inc. Subsets of human natural killer cells with enhanced antibody-directed immune responses
IL278384B2 (en) 2018-05-22 2024-02-01 Immunitybio Inc Optimization of NK-92 cell growth using poloxamer
EP3797149A1 (en) 2018-05-22 2021-03-31 Nantkwest, Inc. Methods and systems for cell bed formation during bioprocessing
CA3098450A1 (en) 2018-05-22 2019-11-28 Nantkwest, Inc. Basal media for growing nk-92 cells
EP3797157A4 (en) 2018-05-22 2022-03-16 ImmunityBio, Inc. FC EPSILON CABIN
US20210267190A1 (en) 2018-07-10 2021-09-02 Nantkwest, Inc. Cryopreservation
WO2020028654A1 (en) 2018-08-01 2020-02-06 Nantkwest, Inc. Combined invasion and cytotoxicity assay using chemokine secreting target cells
KR102653878B1 (ko) 2018-08-01 2024-04-01 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 (a quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies)
KR20200119892A (ko) 2018-10-31 2020-10-20 난트퀘스트, 인크. Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거(elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells)
AU2019370094B2 (en) 2018-10-31 2022-02-03 Nantkwest, Inc. Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells
JP2022533806A (ja) 2018-11-06 2022-07-26 イミュニティーバイオ、インコーポレイテッド キメラ抗原受容体で修飾されたｎｋ－９２細胞
US20240238623A9 (en) * 2018-11-06 2024-07-18 Immunitybio, Inc. Chimeric Antigen Receptor-Modified NK-92 Cells
AU2019388876A1 (en) 2018-11-26 2021-05-20 Immunitybio, Inc. IL-2 Dependent NK-92 cells with stable Fc receptor expression
SG11202105215QA (en) * 2018-12-20 2021-06-29 Kleo Pharmaceuticals Inc Combination therapy of arms and natural killer cells
JP7335001B2 (ja) * 2019-01-18 2023-08-29 アセポディア バイオテクノロジーズ リミテッド 新規ｃｄ１６＋ナチュラルキラーおよびｃｄ１６＋ナチュラルキラー細胞の培養方法
EP3941492A4 (en) * 2019-03-19 2023-05-03 Ramot at Tel-Aviv University Ltd. T-CELL EXPRESSING A FC GAMMA RECEPTOR AND METHODS OF USE THEREOF
JP2022526504A (ja) 2019-03-21 2022-05-25 オーエヌケー セラピューティクス リミテッド 細胞死に対する耐性が増大した改変免疫エフェクター細胞
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
JP2022529502A (ja) 2019-04-23 2022-06-22 サノフイ 抗ｃｄ３８抗体および製剤
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
US20220144952A1 (en) * 2019-08-01 2022-05-12 Nantkwest, Inc. Anti-B7-H4 Chimeric Antigen Receptor-Modified NK-92 Cells
CN114401995A (zh) 2019-08-15 2022-04-26 南特比奥有限公司 TGF-β陷阱
WO2021101467A1 (en) * 2019-11-19 2021-05-27 Acibadem Mehmet Ali̇ Aydinlar Üni̇versi̇tesi̇ A method for redesign and expansion of nk92 cells for use in immunotherapy
CA3159602A1 (en) * 2019-11-20 2021-05-27 Immunitybio, Inc. Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
US20210169931A1 (en) * 2019-12-09 2021-06-10 Nantkwest, Inc. Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2021154218A1 (en) * 2020-01-28 2021-08-05 Nantkwest, Inc. Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
CN113603787B (zh) * 2020-05-04 2023-05-23 英诺康生物医药科技(广州)有限公司 一种非分泌型的人白细胞介素15及应用
CN116194575A (zh) * 2020-06-22 2023-05-30 拉莫特特拉维夫大学有限公司 多亚基蛋白质组件、表达多亚基蛋白质组件的细胞及其用途
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2
EP4108247A1 (en) 2021-06-23 2022-12-28 Ostravska univerzita Urine progenitor cells for use in cancer therapy
WO2023081163A1 (en) 2021-11-02 2023-05-11 Immunitybio, Inc. Natural killer cells for chordoma therapy
EP4180049A1 (en) 2021-11-16 2023-05-17 Ostravska univerzita Therapeutic composition for cancer treatment
US20230323395A1 (en) * 2021-12-15 2023-10-12 Homology Medicines, Inc. Methods and compositions for the production of adeno-associated virus

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3733919A (en) * 1971-09-20 1973-05-22 Adjustable eccentric bearing mountings background
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JP2657221B2 (ja) 1988-05-27 1997-09-24 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ ヒトＦｃγレセプター▲ＩＩＩ▼
US5767077A (en) 1988-05-27 1998-06-16 Applied Research Systems Ars Holding N.V. Human Fc-γ receptor III
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US7038031B1 (en) 1989-07-28 2006-05-02 Sloan-Kettering Institute For Cancer Research DNA encoding FcγR receptor protein on NK cells
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
ES2185705T3 (es) 1994-05-02 2003-05-01 Bernd Groner Proteina bifuncional, preparacion y uso.
KR100343214B1 (ko) * 1995-03-28 2002-11-13 삼성에스디아이 주식회사 전계방출소자의제조방법
US5830725A (en) 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
WO1997033551A2 (en) 1996-03-15 1997-09-18 Millennium Pharmaceuticals Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
WO1998049268A1 (en) * 1997-04-30 1998-11-05 Hans Klingemann Natural killer cell lines and methods of use
US20030026780A1 (en) * 2001-07-18 2003-02-06 Hood Leroy E. Innate immunity mediated methods of treating pathological conditions
WO2003084570A1 (fr) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
US7618617B2 (en) * 2002-05-31 2009-11-17 L'oreal Aqueous hair treatment compositions, thickened with an amphiphilic linear block copolymer
US9902936B2 (en) 2003-07-02 2018-02-27 Innate Pharma S.A. PAN-KIR2DL NK-receptor antibodies and their use in diagnostics and therapy
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
PL2921500T3 (pl) * 2004-07-10 2024-02-05 The Institute For Cancer Research Genetycznie zmodyfikowane ludzkie linie komórkowe naturalni zabójcy
WO2006072626A1 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Kir-binding agents and methods of use thereof

Also Published As

Publication number Publication date
US9181322B2 (en) 2015-11-10
WO2006023148A2 (en) 2006-03-02
CA3052445C (en) 2023-08-22
WO2006023148A8 (en) 2006-05-04
EP2801583B1 (en) 2018-04-25
EP2112162B1 (en) 2015-01-14
CA2572938C (en) 2019-10-15
EP2801583A1 (en) 2014-11-12
CA3052445A1 (en) 2006-03-02
EP2921500A1 (en) 2015-09-23
EP1771471A2 (en) 2007-04-11
EP3406631B1 (en) 2022-06-29
WO2006023148A3 (en) 2006-08-03
ATE443084T1 (de) 2009-10-15
US9150636B2 (en) 2015-10-06
DK2801583T3 (da) 2018-07-16
US7618817B2 (en) 2009-11-17
EP2921500B1 (en) 2023-08-30
DE602005016683D1 (de) 2009-10-29
HK1215269A1 (zh) 2016-08-19
PT2921500T (pt) 2023-09-25
EP2112162A1 (en) 2009-10-28
US20100086996A1 (en) 2010-04-08
US20080247990A1 (en) 2008-10-09
US20160067356A1 (en) 2016-03-10
US20240016957A1 (en) 2024-01-18
PL2921500T3 (pl) 2024-02-05
AU2005277831A1 (en) 2006-03-02
ES2955952T3 (es) 2023-12-11
ES2678094T3 (es) 2018-08-08
US20100086486A1 (en) 2010-04-08
US20230372545A1 (en) 2023-11-23
HK1203975A1 (en) 2015-11-06
US20060292156A1 (en) 2006-12-28
ES2925912T3 (es) 2022-10-20
CA2572938A1 (en) 2006-03-02
DK2921500T3 (da) 2023-09-18
EP3406631A1 (en) 2018-11-28
EP1771471B1 (en) 2009-09-16
US8313943B2 (en) 2012-11-20
AU2005277831A2 (en) 2009-03-12
AU2005277831B2 (en) 2012-11-22
US20130040386A1 (en) 2013-02-14
DK3406631T3 (da) 2022-08-29

Similar Documents

Publication Publication Date Title
DK2921500T3 (da) Genetisk modificerede, humane, naturlige dræbercellelinjer
ECSP056117A (es) Ligandos de receptores de cannabinoides y sus usos
WO2017201432A3 (en) Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
DK1639013T3 (da) Pan-kir2dl-nk-receptor-antistoffer og anvendelse heraf til diagnosticering og terapi
ATE546463T1 (de) Modifizierte humane wachstumshormon-polypeptide und ihre verwendungen
CY1118124T1 (el) Ανακατευθυνομενα, γενετικα τροποποιημενα ρυθμιστικα t-kyttapa και η χρηση τους στην καταστολη της αυτοανοσης και φλεγμονωδους ασθενειας
DK1786439T3 (da) Fremgangsmåder til aktivering af NKT-celler
ATE475669T1 (de) Einen modifizierten t-zellen-rezeptor exprimierende zellen
BRPI0519430A2 (pt) hormânio do crescimento humano modificado
IL186986A0 (en) Compositions and methods for modulating immune responses
DE122012000028I1 (de) Vorrichtung auf polymerbasis mit verzogerter freisetzung.
TW200531679A (en) Methods of modulating cytokine activity; related reagents
WO2008033403A3 (en) Agents and methods to elicit anti-tumor immune response
EA200501430A1 (ru) Лиганды каннабиноидных рецепторов и их применение
DE602005020837D1 (de) Il-7-varianten mit reduzierter immunogenität
MX2007007602A (es) Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos.
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
ECSP045382A (es) Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa
ATE393169T1 (de) Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
DK1565183T3 (da) Rapamycin og IL-10 til behandling af autoimmune sygdomme
DE602006002894D1 (de) Naphthyridinverbindungen
GT200000200A (es) Compuestos de 2,4-diamino-pirimidina utiles como supresores de inmunidad.
EA200801180A1 (ru) Селективные пептидные агонисты рецептора vpac2
ATE389670T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
GT200300199A (es) Indoles 2,7-sustituidos